Cite
HARVARD Citation
Hellmann, M. et al. (2015). An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227). Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].